CN1558907A - 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑 - Google Patents

作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑 Download PDF

Info

Publication number
CN1558907A
CN1558907A CNA018159702A CN01815970A CN1558907A CN 1558907 A CN1558907 A CN 1558907A CN A018159702 A CNA018159702 A CN A018159702A CN 01815970 A CN01815970 A CN 01815970A CN 1558907 A CN1558907 A CN 1558907A
Authority
CN
China
Prior art keywords
compound
pharmaceutical composition
treatment
compounds
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018159702A
Other languages
English (en)
Chinese (zh)
Inventor
辛南阳
R·G·艾斯拉南
�����Ƥ��
J·J·皮温斯基
Сԭ½��
A·T·小陆波
A·艾佛梭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1558907A publication Critical patent/CN1558907A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA018159702A 2000-09-20 2001-09-18 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑 Pending CN1558907A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23403800P 2000-09-20 2000-09-20
US60/234,038 2000-09-20

Publications (1)

Publication Number Publication Date
CN1558907A true CN1558907A (zh) 2004-12-29

Family

ID=22879621

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018159702A Pending CN1558907A (zh) 2000-09-20 2001-09-18 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑

Country Status (14)

Country Link
US (1) US6528522B2 (enExample)
EP (1) EP1318993B1 (enExample)
JP (1) JP2004509869A (enExample)
CN (1) CN1558907A (enExample)
AR (1) AR031612A1 (enExample)
AT (1) ATE405557T1 (enExample)
AU (1) AU2001291040A1 (enExample)
CA (1) CA2422210C (enExample)
DE (1) DE60135471D1 (enExample)
ES (1) ES2311544T3 (enExample)
HK (1) HK1052180A1 (enExample)
MX (1) MXPA03002445A (enExample)
MY (1) MY120281A (enExample)
WO (1) WO2002024657A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2014130534A1 (en) * 2013-02-19 2014-08-28 Icahn School Of Medicine At Mount Sinai Tricyclic heterocycles as anticancer agents
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
CA2997769A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
CN108349961B (zh) 2015-09-09 2022-02-18 西奈山伊坎医学院 杂环受限三环磺酰胺作为抗癌试剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
DK0448765T3 (da) 1990-03-30 1994-09-19 Heumann Pharma Gmbh & Co Anvendelse af guanidinderivater til fremstilling af et lægemiddel med NPY-antagonistisk virkning
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
WO1993012093A1 (en) 1991-12-18 1993-06-24 Schering Corporation Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
NZ330898A (en) 1993-11-15 2000-01-28 Schering Corp Phenyl-alkyl imidazoles as H3-receptor antagonists in particular for the treatment of inflammation
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
PT1019050E (pt) 1997-06-24 2002-09-30 Novo Nordisk As Utilizacao de agonisticos e de antagonisticos de somatostatina para o tratamento de doencas associadas ao olho
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses

Also Published As

Publication number Publication date
CA2422210A1 (en) 2002-03-28
MY120281A (en) 2005-09-30
JP2004509869A (ja) 2004-04-02
EP1318993A2 (en) 2003-06-18
AU2001291040A1 (en) 2002-04-02
EP1318993B1 (en) 2008-08-20
AR031612A1 (es) 2003-09-24
MXPA03002445A (es) 2003-06-19
US6528522B2 (en) 2003-03-04
HK1052180A1 (zh) 2003-09-05
WO2002024657A3 (en) 2002-07-11
ATE405557T1 (de) 2008-09-15
WO2002024657A2 (en) 2002-03-28
US20020082272A1 (en) 2002-06-27
CA2422210C (en) 2009-10-27
DE60135471D1 (de) 2008-10-02
ES2311544T3 (es) 2009-02-16

Similar Documents

Publication Publication Date Title
CN1273450C (zh) 作为5－羟色胺－6配体的1－芳基或1－烷基磺酰基吲哚衍生物
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1198817C (zh) 作为组胺－h3激动剂或拮抗剂的n－(咪唑基烷基)取代的环胺
CN1434806A (zh) 取代的咪唑神经肽yy5受体拮抗剂
CN1349524A (zh) 血管紧张肽原酶抑制剂
CN1659162A (zh) 三环凝血酶受体拮抗剂
CN1146559C (zh) 毒蕈碱性拮抗剂
CN1589269A (zh) 杂1,2－二氢化茚:一类新型有效的大麻配体
CN1409703A (zh) 4－氨基哌啶衍生物和它们作为药物的用途
CN1177844C (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
CN1649845A (zh) 蝇蕈碱拮抗剂
CN1608050A (zh) 哌嗪衍生物
CN1492863A (zh) 作为5-羟色胺-6配基的杂环基烷基-吲哚或氮杂吲哚化合物
CN1795186A (zh) 代谢型谷氨酸受体－5的二芳基取代三唑调节剂
CN1768055A (zh) 作为代谢型谷氨酸受体－5调制剂的四环咪唑衍生物
CN1798744A (zh) 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物
CN1461304A (zh) 作为双组织胺h1和h3促效剂或拮抗剂的取代的咪唑类化合物
CN1461303A (zh) 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑
CN1167682C (zh) 毒蕈碱拮抗剂
CN1184964C (zh) 羰基氨基衍生物对抗cns障碍的应用
CN1558907A (zh) 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑
CN1285828A (zh) 被含有一个氮原子的五、六或七元杂环取代的咪唑基烷基
CN1875016A (zh) 咪唑衍生物
CN1461299A (zh) 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑
CN1823054A (zh) 咪唑衍生物ⅲ

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication